Goldman SachsGSPAST TOP PICKMay 17, 2017Stock price when the opinion was issued
As of Jul 21, 2026. Market Open.
Different businesses. LLY is a big play in GLP-1 drugs. How will pills effect the injections business? LLY has done a good job of navigating these new pills. GS enjoys increased stock market and IPO businesses. He prefers LLY, which is tied to a secular growth trend, but GS' good times in capturing revenue in this cycle will end.
Mergers are increasing, and banks like GS makes advisory fees from them. Also, the banks have been rallying since oil slumped, and will benefit further from rising interest rates, which appears will happen later this year. Plus, hyperscalers may need to keep borrowing money to keep competing with each other.
(A Top Pick March 2/16. Up 30.36%.) There is still more to go on this. There is a dearth of US companies right now. The number of listed US companies is shrinking year by year for the last 10 years. Expects that this is going to go up towards its high of the year of about $250.